Your browser doesn't support javascript.
loading
68Ga-PSMA-11 PET/CT in patients with occult biochemical recurrence of prostate carcinoma and negative 18F-Choline PET/CT. Preliminary assessment of its clinical use.
Plaza López, P J; Puertas, E; Aguiló, J J; Suarez-Piñera, M; Domenech, B; Mestre-Fusco, A; Casals, J; Chicharo de Fleitas, J R.
Afiliación
  • Plaza López PJ; Servicio de Medicina Nuclear, Hospital Quironsalud Barcelona, Barcelona, Spain. Electronic address: pedro.plaza@quironsalud.es.
  • Puertas E; Servicio de Radioterapia, Hospital Quironsalud Barcelona, Barcelona, Spain.
  • Aguiló JJ; Servicio de Urología, Hospital Quironsalud Barcelona, Barcelona, Spain.
  • Suarez-Piñera M; Servicio de Medicina Nuclear, Hospital del Mar, Barcelona, Spain.
  • Domenech B; Servicio de Medicina Nuclear, Hospital Quironsalud Barcelona, Barcelona, Spain.
  • Mestre-Fusco A; Servicio de Medicina Nuclear, Hospital del Mar, Barcelona, Spain.
  • Casals J; Servicio de Radioterapia, Hospital Quironsalud Barcelona, Barcelona, Spain.
  • Chicharo de Fleitas JR; Unidad de Imagen Molecular, CIMES-FGUMA, Málaga, Spain.
Actas Urol Esp (Engl Ed) ; 45(5): 353-358, 2021 Jun.
Article en En, Es | MEDLINE | ID: mdl-34088434
OBJECTIVE: To assess the clinical usefulness of 68Ga-PSMA PET/CT studies in patients with occult biochemical recurrence of prostate carcinoma, with negative or inconclusive radiologic and 18 F-Choline PET/CT imaging studies. MATERIAL AND METHODS: Retrospective descriptive study. The first 14 patients with a history of prostate carcinoma, treated with curative intent and presenting suspicion of biochemical recurrence with low PSA values (<3 ng/mL) were selected. Imaging studies, prostate ultrasound, pelvic CT and/or MRI were negative, and all of them had a negative or inconclusive 18F-Choline PET/CT. All patients were referred to 68 Ga-PSMA-11 PET/CT. PROTOCOL: Dose 2.2 M Bq/kg. 20 mg furosemide at start. PET/CT images from skull base to proximal third of thighs at 60 min, and late images at 3 h if needed. RESULTS: The 68 Ga-PSMA-11 PET/CT was able to localize the occult biochemical recurrence in 9 of the 14 patients (64.2%), and it affected the therapeutic attitude in all of them. Four patients (28.5%) obtained a negative or inconclusive 68 Ga-PSMA-11 PET/CT and continued under vigilant approach with PSA controls and imaging studies according to the clinical guidelines. These patients had the lowest PSA values (less than 1 ng/mL). One of the 68 Ga-PSMA-11 PET/CT studies was inconclusive, reporting the presence of a doubtful right iliac adenopathy. CONCLUSION: 68 Ga-PSMA-11 PET/CT allows an early diagnosis, with low PSA values, of occult biochemical recurrence of prostate carcinoma, even in patients with negative 18 F-Choline PET/CT.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Carcinoma Tipo de estudio: Guideline / Observational_studies / Screening_studies Límite: Humans / Male Idioma: En / Es Revista: Actas Urol Esp (Engl Ed) Año: 2021 Tipo del documento: Article Pais de publicación: España
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Carcinoma Tipo de estudio: Guideline / Observational_studies / Screening_studies Límite: Humans / Male Idioma: En / Es Revista: Actas Urol Esp (Engl Ed) Año: 2021 Tipo del documento: Article Pais de publicación: España